Mebendazole and Cancer Research: What Patients Should Know About Repurposed Drugs

Mebendazole, often called MBZ, is an older prescription medication traditionally used to treat certain parasitic infections. In recent years, it has gained attention in cancer research because some laboratory and early clinical studies have explored whether it may have activity against certain cancer pathways.

This interest is part of a broader field called drug repurposing, where researchers study existing medications for possible new uses. Because these drugs may already have known safety profiles for their approved uses, they can sometimes become candidates for further research in other areas of medicine.

However, it is important to be clear: mebendazole is not an FDA-approved cancer treatment, and it should never be used as a replacement for oncology care, chemotherapy, radiation, surgery, immunotherapy, targeted therapy, or any physician-recommended cancer treatment plan.

What Is Mebendazole?

Mebendazole is a broad-spectrum antihelminthic medication used for certain parasitic worm infections. It has been used for decades and is available as a prescription medication in the United States.

Because it has an established role in treating parasitic infections, researchers have examined whether mebendazole may have additional biological effects that could be relevant to cancer research.

Why Are Researchers Studying Repurposed Drugs?

Developing new cancer medications can take many years. Drug repurposing looks at existing medications to determine whether they may have potential in new therapeutic areas.

In oncology research, repurposed drugs are sometimes studied because they may affect cancer-related pathways such as:

• Cell division
• Tumor growth signals
• Cancer cell survival
• Metabolic activity
• Inflammatory pathways
• Treatment resistance

These studies are still highly controlled research areas and do not mean that a medication is proven or approved for cancer treatment.

Mebendazole and Cancer Research

Preclinical studies have explored mebendazole’s potential activity in cancer models, including its possible effects on cancer cell division, microtubule function, cell death pathways, and tumor growth behavior.

Researchers have studied mebendazole in relation to several cancers, including:

• Glioblastoma and other brain cancers
• Colon and gastric cancers
• Lung cancer
• Breast cancer
• Triple-negative breast cancer
• Head and neck squamous cell cancers
• Melanoma
• Ovarian cancer
• Prostate cancer
• Malignant meningiomas

While these areas of research are scientifically interesting, much of the evidence remains early-stage, preclinical, or limited. More clinical research is needed to determine safety, dosing, effectiveness, interactions, and appropriate patient selection in oncology settings.

Important Safety Considerations

Even though mebendazole has a known safety profile for its approved use, cancer-related dosing and long-term off-label use may involve different risks.

Potential safety considerations may include:

• Liver function concerns
• Drug interactions
• Blood count changes
• Gastrointestinal side effects
• Pregnancy and breastfeeding considerations
• Interactions with chemotherapy or other cancer treatments

Patients should never begin mebendazole for cancer support without guidance from their oncologist or qualified healthcare provider.

Off-Label Use Should Be Provider-Guided

Some medications are prescribed off-label when a healthcare provider determines it is appropriate for an individual patient. Off-label use does not mean a medication is unsafe, but it does mean the use has not been specifically approved by the FDA for that condition.

For patients with cancer, off-label medication decisions should be made carefully by an oncology team that can evaluate:

• Cancer type and stage
• Current treatment plan
• Lab values
• Liver and kidney function
• Current medications
• Potential interactions
• Goals of care
• Available clinical evidence

A Pharmacist’s Role in Cancer Support

Pharmacists can help patients and providers better understand medication questions, potential interactions, dosing concerns, and safety considerations. For patients exploring repurposed drug research, pharmacist involvement can be valuable as part of a provider-directed care team.

Pharmacy Solutions can help support conversations between patients and providers when medication questions arise, especially when safety, interactions, or individualized care planning are involved.

Final Takeaway

Mebendazole is an older medication with an established use for parasitic infections and a growing body of research interest in oncology. While some studies have explored its potential role in cancer-related pathways, it is not approved as a cancer treatment and should not be used without medical supervision.

Patients interested in mebendazole or other repurposed drug research should speak directly with their oncologist before making any treatment decisions.